Search results for "agonist"

showing 10 items of 2285 documents

Topical prazosin attenuates sensitivity to tactile stimuli in patients with complex regional pain syndrome

2015

Background The sympathetic nervous system may play an important role in certain forms of chronic pain. The main aim of this study was to determine whether functional blockade of α1-adrenoceptors would alter sensitivity to cutaneous stimulation in patients with complex regional pain syndrome (CRPS). Methods and Results In an initial study, high-performance liquid chromatography-mass spectrometry of intradermal interstitial fluid collected from the forearms of three healthy individuals established that the α1-adrenoceptor antagonist prazosin penetrated the skin barrier when mixed in Lipoderm® cream base. Next, we found that application of this cream to the forearm of 10 healthy participants a…

AdultMaleSympathetic nervous systemAdministration Topical03 medical and health sciences0302 clinical medicine030202 anesthesiologyReflexmedicinePrazosinHumansbusiness.industryChronic painPrazosinMiddle Agedmedicine.diseaseVasodilationForearmAnesthesiology and Pain MedicineComplex regional pain syndromeAllodyniamedicine.anatomical_structureHyperalgesiaAnesthesiaHyperalgesiaAdrenergic alpha-1 Receptor AntagonistsReflexFemaleAxon reflexmedicine.symptombusinessComplex Regional Pain Syndromes030217 neurology & neurosurgerymedicine.drugEuropean Journal of Pain
researchProduct

Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: New insights for an old treatment

2022

Although splenectomy is still considered the most effective curative treatment for immune thrombocytopenia (ITP), its use has significantly declined in the last decade, especially since the approval of thrombopoietin receptor agonists (TPO-RAs). The main objective of the study was to determine whether splenectomy was still as effective nowadays, particularly for patients with failure to respond to TPO-RAs. Our secondary objective was to assess, among patients who relapsed after splenectomy, the pattern of response to treatments used before splenectomy. This multicentre retrospective study involved adults who underwent splenectomy for ITP in France from 2011 to 2020. Response status was defi…

AdultMaleThrombopoietin Receptor Agonistsmedicine.medical_specialtymedicine.medical_treatmentSplenectomy[SDV.CAN]Life Sciences [q-bio]/CancerGastroenterology[SDV.CAN] Life Sciences [q-bio]/CancerInternal medicineHumansMedicineRetrospective StudiesPurpura Thrombocytopenic Idiopathicbusiness.industryRetrospective cohort studyHematologyMiddle AgedImmune thrombocytopeniaTreatment OutcomeCurative treatmentSustained responseSplenectomyFemaleRituximabRituximabbusinessReceptors Thrombopoietinmedicine.drugAmerican Journal of Hematology
researchProduct

Time Course of 5-HT2A Receptor Occupancy in the Human Brain after a Single Oral Dose of the Putative Antipsychotic Drug MDL 100,907 Measured by Posit…

1997

MDL 100,907 is a potent and selective antagonist of 5-HT2A serotonin receptors. Animals studies suggest that MDL 100,907 may behave as an atypical antipsychotic drug. Positron emission tomograph (PET) using [11C]NMSP as the radiotracer was used to define the time course of 5-HT2 receptor occupancy in the human frontal cerebral cortex after a single oral dose of MDL 100,907 (10 or 20 mg) in nine healthy subjects. After the baseline scan each subject was studied three times post dosing at various time points. 5-HT2 occupancies were in the range of 70 and 90% after each dose. While the occupancy remains in this range over 24 hours after 20 mg MDL 100,907, it decreases by about 20% at 24 hours …

AdultMaleTime Factorsmedicine.drug_classAtypical antipsychoticPharmacologyPiperidinesOral administrationmedicineHumansReceptor Serotonin 5-HT2ACarbon RadioisotopesPositron emissionDosing5-HT receptorPharmacologymedicine.diagnostic_testbusiness.industry5-HT2 receptorBrainHuman brainFluorobenzenesPsychiatry and Mental healthmedicine.anatomical_structureSpiperonePositron emission tomographyReceptors SerotoninFemaleSerotonin AntagonistsbusinessAntipsychotic AgentsTomography Emission-ComputedNeuropsychopharmacology
researchProduct

Impact of Heavy Polypropylene Mesh and Composite Light Polypropylene and Polyglactin 910 on the Inflammatory Response

2010

The aim of the study was to analyze the acute inflammatory response after implantation of a heavyweight mesh of polypropylene (PP) compared with a composite mesh of light PP and polyglactin 910 (PG) in patients undergoing inguinal hernioplasty. A total of 30 male patients with inguinal hernia were included in the study and divided into 2 groups (PP and PP-PG) according to the mesh used. Changes of leukocytes, cytokines, growth factors, and acute phase proteins were evaluated in the sera. Leukocytes and acute phase proteins were significantly increased postoperatively in both groups, and the values were slightly higher in the PP group. Cytokine levels were significantly increased postoperat…

AdultMaleVascular Endothelial Growth Factor Amedicine.medical_specialtymedicine.medical_treatmentInflammatory responseUrologyBiocompatible MaterialsHernia InguinalPolypropylenesProinflammatory cytokinechemistry.chemical_compoundTransforming Growth Factor betaHumansMedicineHerniaPolyglactin 910AgedInflammationPolypropyleneInterleukin-6business.industryPolyglactin 910Acute-phase proteinMiddle AgedSurgical Meshmedicine.diseaseSurgeryFibroblast Growth FactorsInterleukin 1 Receptor Antagonist ProteinInguinal herniaC-Reactive ProteinCytokinechemistrySurgerybusinessSurgical Innovation
researchProduct

Contractile responses of human thyroid arteries to vasopressin

2013

Abstract Aims In the present study we investigated the intervention of nitric oxide and prostacyclin in the responses to vasopressin of isolated thyroid arteries obtained from multi-organ donors. Main methods Paired artery rings from glandular branches of the superior thyroid artery, one normal and the other deendothelised, were mounted in organ baths for isometric recording of tension. Concentration–response curves to vasopressin were determined in the absence and in the presence of either the vasopressin V 1 receptor antagonist d(CH 2 ) 5 Tyr(Me)AVP (10 − 8  M), the nitric oxide synthase inhibitor N G -monomethyl- l -arginine ( L -NMMA, 10 − 4  M), or the inhibitor of prostaglandins indom…

AdultMaleVasopressinmedicine.medical_specialtyEndotheliumVasopressinsIndomethacinThyroid GlandProstacyclinIn Vitro TechniquesGeneral Biochemistry Genetics and Molecular BiologyNitric oxideSuperior thyroid arterychemistry.chemical_compoundmedicine.arteryInternal medicinemedicineHumansDrug InteractionsGeneral Pharmacology Toxicology and PharmaceuticsAgedVasopressin receptoromega-N-MethylarginineDose-Response Relationship DrugbiologyChemistryThyroidArteriesGeneral MedicineMiddle AgedArginine VasopressinNitric oxide synthaseEndocrinologymedicine.anatomical_structureVasoconstrictionbiology.proteinFemalehormones hormone substitutes and hormone antagonistsmedicine.drugLife Sciences
researchProduct

Endothelium-independent contractions of human cerebral arteries in response to vasopressin.

1990

We studied the effects of vasopressin in isolated segments from branches (500-700 micrograms in external diameter) of human middle cerebral arteries obtained during autopsy of 15 patients who had died 3-8 hours before. Paired segments, one normal and the other de-endothelized by gentle rubbing, were mounted for isometric recording of tension in organ baths. In 11 normal segments, vasopressin produced concentration-dependent contractions with an EC50 of 7.0 X 10(-10) M. Removal of the endothelium from 12 segments did not significantly affect vasopressin-induced contractions. Vasopressin produced further contractions in arterial segments with (n = 4) or without (n = 5) endothelium precontract…

AdultMaleVasopressinmedicine.medical_specialtyEndotheliummedicine.drug_classVasopressinsCerebral arteriesNeuropeptideIn Vitro TechniquesPotassium Chloridemedicine.arteryInternal medicinemedicineHumansAgedAdvanced and Specialized NursingDose-Response Relationship Drugbusiness.industryOsmolar ConcentrationCerebral ArteriesMiddle AgedReceptor antagonistAcetylcholineArginine Vasopressinmedicine.anatomical_structureEndocrinologyVasoconstrictionMiddle cerebral arteryFemaleNeurology (clinical)Endothelium Vascularmedicine.symptomCardiology and Cardiovascular MedicinebusinessAcetylcholineVasoconstrictionmedicine.drugStroke
researchProduct

Effects of vasopressin on human renal arteries

1996

The effects of vasopressin were studied in isolated rings from branches (2-3 mm in external diameter) of human renal arteries obtained from 18 patients undergoing nephrectomy for non-obstructive neoplasia. In arterial rings under resting tension, vasopressin produced concentration-dependent and endothelium-independent contractions with an EC 50 of 9.1 x 10 -10 mol L -1 . The vasopressin V 1 receptor antagonist d(CH 2 ) 5 Tyr(Me)AVP (10 -6 mol L -1 ) displaced the control curve to vasopressin 564-fold to the right in a parallel manner. In precontracted arterial rings and previously treated with the V 1 antagonist (10 -6 mol L -1 ) vasopressin caused endothelium-independent relaxation. The re…

AdultMaleVasopressinmedicine.medical_specialtyVasopressinsmedicine.drug_classMuscle RelaxationIndomethacinClinical BiochemistryNeuropeptideBiologyBiochemistryNorepinephrineRenal ArteryInternal medicinemedicineHumansVasoconstrictor AgentsAgedVasopressin receptorKidneyDose-Response Relationship DrugAnti-Inflammatory Agents Non-SteroidalAntagonistGeneral MedicineMiddle AgedReceptor antagonistmedicine.anatomical_structureEndocrinologyCirculatory systemFemaleEndothelium Vascularmedicine.symptomhormones hormone substitutes and hormone antagonistsVasoconstrictionMuscle ContractionEuropean Journal of Clinical Investigation
researchProduct

Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain

2007

What is already known about this subject • Despite encouraging effects of N-methyl-D-aspartate (NMDA) receptor antagonists in reducing neuropathic pain of different aetiologies, the clinical use of these agents has been limited by their mainly psychotropic side-effects. • In a recent study in healthy volunteers, CNS 5161, a novel noncompetetive NMDA receptor antagonist, was well tolerated up to a dosage of 2000 µg without psychotropic side-effects. • This is the first study to evaluate the maximal tolerated dosage of CNS 5161 and to gain experience about the analgesic effect of CNS 5161 in patients with different pain syndromes. What this study adds • In patients with neuropathic pain CNS 5…

AdultMaleVisual analogue scaleAnalgesicPlaceboGuanidinesReceptors N-Methyl-D-Aspartatechemistry.chemical_compoundDrug SafetyDouble-Blind MethodMedicineHumansPharmacology (medical)Glutamate receptor antagonistSulfhydryl CompoundsAdverse effectAgedPain MeasurementPharmacologyCross-Over StudiesDose-Response Relationship Drugbusiness.industryTherapeutic effectMiddle AgedBlood pressurechemistryAnesthesiaNeuropathic painNeuralgiaFemalebusiness
researchProduct

Testosterone-Lowering Medication and Its Association With Recidivism Risk in Individuals Convicted of Sexual Offenses

2020

For a particular subgroup of individuals with severe paraphilic disorders and a high risk of sexual recidivism, the combination of sex drive–reducing medications and psychotherapy is a promising treatment approach. The present quasi-experimental study aims at comparing differences in clinical characteristics and dynamic risk factors between persons receiving (+TLM, n = 38) versus not receiving (−TLM, n = 22) testosterone-lowering medications (TLMs). Individuals receiving TLM were more frequently diagnosed with paraphilic disorders. Neither the criminal history nor average risk scores differed between the two groups. In the +TLM, Stable-2007 scores showed a stronger decrease after TLM treat…

AdultMaleantiandrogensTreatment durationPsychopathySelf-ControlRisk FactorsGermanyparaphilic disordermedicineHumansTestosteroneAssociation (psychology)General PsychologyAgedAverage riskDuration of TherapyRecidivismParaphilic DisordersSex Offensesrisk assessmentAndrogen Antagonistssexual offender treatmentTestosterone (patch)ArticlesCriminalsMiddle Agedmedicine.diseaseGnRH-agonistsCriminal historyPsychotherapyPsychiatry and Mental healthTreatment OutcomeRecidivismRisk assessmentPsychologyClinical psychologySexual Abuse
researchProduct

Thyroid function and release of thyroid-stimulating hormone and prolactin from the pituitary in human obesity

1991

Thyroid function, basal serum thyroid-stimulating hormone (TSH) and prolactin concentrations, and the effects of 200 micrograms TSH-releasing hormone (TRH) given intravenously on TSH (delta TSH) and prolactin (delta prolactin) were investigated in 25 euthyroid obese subjects and 20 lean controls. No significant differences in serum thyroid hormone concentrations, glucose metabolism parameters, or basal TSH and prolactin concentrations were detected between groups, but a significant (P less than 0.01) increase in delta TSH and a significant (P less than 0.01) decrease in delta prolactin were observed in obese subjects. No significant differences in basal TSH and prolactin were observed in ob…

AdultMaleendocrine system030213 general clinical medicinemedicine.medical_specialtyTime Factorsendocrine system diseasesThyroid GlandThyrotropin030209 endocrinology & metabolismPeptide hormoneBiochemistry03 medical and health sciencesBasal (phylogenetics)0302 clinical medicineSex FactorsThyroid-stimulating hormoneInternal medicinemedicineHumansEuthyroidObesityThyrotropin-Releasing Hormonebusiness.industryBiochemistry (medical)ThyroidCell BiologyGeneral MedicineProlactinProlactinmedicine.anatomical_structureEndocrinologyPituitary GlandFemaleThyroid functionbusinesshormones hormone substitutes and hormone antagonistsHormone
researchProduct